REASONS FOR PERFORMING STUDY: A consistent and clinically relevant model for the induction of core lesions confined to the mid-metacarpal superficial digital flexor tendon (SDFT) has not been previously reported. Injection of bacterial collagenase is commonly used but often results in large, irregular and inconsistent lesions that disrupt the superficial tendon layers and epitenon. OBJECTIVE: To develop and evaluate a new injection technique for collagenase induction of SDFT injury. METHODS: Collagenase gel was injected into a physical columnar defect created by longitudinally placing a curved 16 gauge 8.89 cm needle in the mid-metacarpal SDFT in a randomly selected forelimb of 10 horses. A placebo treatment injection was performed 1 week later. Serial ultrasound examinations were performed. Horses were subjected to euthanasia at 2 (n = 2), 4 (n = 2), 8 (n = 4) and 16 (n = 2) weeks post treatment injection. Post mortem magnetic resonance imaging and histological analysis were performed. Gene expression (18S, SCX, TNC, TNMD, COL1A1, COL3A1, COMP, DCN, MMP1, MMP3 and MMP13), total DNA, glycosaminoglycan and collagen content were determined for experimental tendons (n = 10) and unaffected tendons (n = 9). RESULTS: Mid-metacarpal SDFT core lesion induction was successful in all tendons with consistent lesion cross-sectional area and minimal epitenon disruption. Histology confirmed loss of normal tendon architecture after tendonitis induction and subsequent healing of the tendon core lesion. Compared with gene expression in unaffected tendons, several tested genes were significantly upregulated (COL1A1, COL3A1, TNMD, SCX, TNC, MMP13), while others showed significant downregulation (COMP, DCN, and MMP3). CONCLUSION: Compared with the previously used direct injection of collagenase, this injection technique was easily performed and induced more consistent lesions that were mid-metacarpal and did not disrupt the epitenon. POTENTIAL RELEVANCE: This model will allow for objective assessment of therapies for tendon regeneration in the mid-metacarpal SDFT prior to clinical trials and routine clinical application.
REASONS FOR PERFORMING STUDY: A consistent and clinically relevant model for the induction of core lesions confined to the mid-metacarpal superficial digital flexor tendon (SDFT) has not been previously reported. Injection of bacterial collagenase is commonly used but often results in large, irregular and inconsistent lesions that disrupt the superficial tendon layers and epitenon. OBJECTIVE: To develop and evaluate a new injection technique for collagenase induction of SDFT injury. METHODS: Collagenase gel was injected into a physical columnar defect created by longitudinally placing a curved 16 gauge 8.89 cm needle in the mid-metacarpal SDFT in a randomly selected forelimb of 10 horses. A placebo treatment injection was performed 1 week later. Serial ultrasound examinations were performed. Horses were subjected to euthanasia at 2 (n = 2), 4 (n = 2), 8 (n = 4) and 16 (n = 2) weeks post treatment injection. Post mortem magnetic resonance imaging and histological analysis were performed. Gene expression (18S, SCX, TNC, TNMD, COL1A1, COL3A1, COMP, DCN, MMP1, MMP3 and MMP13), total DNA, glycosaminoglycan and collagen content were determined for experimental tendons (n = 10) and unaffected tendons (n = 9). RESULTS: Mid-metacarpal SDFT core lesion induction was successful in all tendons with consistent lesion cross-sectional area and minimal epitenon disruption. Histology confirmed loss of normal tendon architecture after tendonitis induction and subsequent healing of the tendon core lesion. Compared with gene expression in unaffected tendons, several tested genes were significantly upregulated (COL1A1, COL3A1, TNMD, SCX, TNC, MMP13), while others showed significant downregulation (COMP, DCN, and MMP3). CONCLUSION: Compared with the previously used direct injection of collagenase, this injection technique was easily performed and induced more consistent lesions that were mid-metacarpal and did not disrupt the epitenon. POTENTIAL RELEVANCE: This model will allow for objective assessment of therapies for tendon regeneration in the mid-metacarpal SDFT prior to clinical trials and routine clinical application.
Authors: Ashlee E Watts; Neal L Millar; Josh Platt; Susan M Kitson; Moeed Akbar; Raquel Rech; Jay Griffin; Roy Pool; Tom Hughes; Iain B McInnes; Derek S Gilchrist Journal: Mol Ther Date: 2017-07-28 Impact factor: 11.454
Authors: Franziska C Wagner; Sven Reese; Kerstin Gerlach; Peter Böttcher; Christoph K W Mülling Journal: BMC Vet Res Date: 2021-06-25 Impact factor: 2.741
Authors: Fredrik Södersten; Kjell Hultenby; Dick Heinegård; Christopher Johnston; Stina Ekman Journal: Connect Tissue Res Date: 2012-12-03 Impact factor: 3.417
Authors: Else Jacobson; Else Jacobsen; Andrew J Dart; Takamitsu Mondori; Neil Horadogoda; Leo B Jeffcott; Christopher B Little; Margaret M Smith Journal: PLoS One Date: 2015-04-02 Impact factor: 3.240
Authors: Angela M Gaesser; Claire Underwood; Renata L Linardi; Kayla M Even; Virginia B Reef; Snehal S Shetye; Robert L Mauck; William J King; Julie B Engiles; Kyla F Ortved Journal: Front Vet Sci Date: 2021-07-05
Authors: Armando de Mattos Carvalho; Peres Ramos Badial; Luis Emiliano Cisneros Álvarez; Ana Lucia Miluzzi Yamada; Alexandre Secorun Borges; Elenice Deffune; Carlos Alberto Hussni; Ana Liz Garcia Alves Journal: Stem Cell Res Ther Date: 2013-07-22 Impact factor: 6.832
Authors: Roland S Camenzind; Timo O Tondelli; Tobias Götschi; Claude Holenstein; Jess G Snedeker Journal: Clin Orthop Relat Res Date: 2018-05 Impact factor: 4.176
Authors: Sara Biasutti; Andrew Dart; Margaret Smith; Carina Blaker; Elizabeth Clarke; Leo Jeffcott; Christopher Little Journal: PLoS One Date: 2017-10-12 Impact factor: 3.240